Biomarker Testing in NSCLC

Review this slideset on current recommendations for evidence-based biomarker testing to guide treatment decision-making for patients with NSCLC from Matthew Gubens, MD, MS, and Craig Mackinnon, MD, PhD.
Matthew Gubens, MD, MS
Craig Mackinnon, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 7.86 MB
Released: July 6, 2022


Provided by Clinical Care Options, LLC in partnership with the Association for Molecular Pathology

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with
Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation

Related Content

Experts highlight key studies being presented at the upcoming 2022 WCLC annual meeting in this commentary from Clinical Care Options (CCO)

Wade T. Iams, MD, MSCI Heather Wakelee, MD Released: August 5, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset on the molecular determinants for the selection of optimal therapy for patients with NSCLC, from Clinical Care Options (CCO)

Matthew Gubens, MD, MS Craig Mackinnon, MD, PhD Released: July 29, 2022

Video featuring nursing perspective on biomarker testing in NSCLC and targeted therapy for actionable genomic alterations, from Clinical Care Options (CCO)

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Registered Nurses: 1.0 Nursing contact hour Released: July 27, 2022 Expired: July 26, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings